Cognitive Impairment in Genetic Parkinson's Disease

Overview

Journal Parkinsons Dis

Publisher Wiley

Date 2022 Jan 10

PMID 35003622

Authors

A Planas-Ballve

D Vilas

Affiliations

Soon will be listed here.

Abstract

Cognitive impairment is common in idiopathic Parkinson's disease (PD). Knowledge of the contribution of genetics to cognition in PD is increasing in the last decades. Monogenic forms of genetic PD show distinct cognitive profiles and rate of cognitive decline progression. Cognitive impairment is higher in and -associated PD, lower in and -PD, and possibly milder in 2-PD. In this review, we summarize data regarding cognitive function on clinical studies, neuroimaging, and biological markers of cognitive decline in autosomal dominant PD linked to mutations in and , autosomal recessive PD linked to and and also PD linked to mutations.

Citing Articles

Mitochondrial Dysfunction in Parkinson's Disease: A Contribution to Cognitive Impairment?.

Scorziello A, Sirabella R, Sisalli M, Tufano M, Giaccio L, DApolito E Int J Mol Sci. 2024; 25(21).

PMID: 39519043 PMC: 11546611. DOI: 10.3390/ijms252111490.

Associations between cognitive screening performance and motor symptoms in Parkinson's disease:a systematic review and meta-analysis.

Patrick K, Cousins E, Spitznagel M Dement Neuropsychol. 2024; 18:e20230102.

PMID: 39258165 PMC: 11386525. DOI: 10.1590/1980-5764-DN-2023-0102.

Genetics in parkinson's disease: From better disease understanding to machine learning based precision medicine.

Aborageh M, Krawitz P, Frohlich H Front Mol Med. 2024; 2:933383.

PMID: 39086979 PMC: 11285583. DOI: 10.3389/fmmed.2022.933383.

Enhanced Spine Stability and Survival Lead to Increases in Dendritic Spine Density as an Early Response to Local Alpha-Synuclein Overexpression in Mouse Prefrontal Cortex.

Bosch P, Kerr G, Cole R, Warwick C, Wendt L, Pradeep A Cell Mol Neurobiol. 2024; 44(1):42.

PMID: 38668880 PMC: 11052719. DOI: 10.1007/s10571-024-01472-7.

GBA moderates cognitive reserve's effect on cognitive function in patients with Parkinson's disease.

Chang C, Tan C, Hong W, Yu R J Neurol. 2024; 271(7):4392-4405.

PMID: 38656622 DOI: 10.1007/s00415-024-12374-5.

References

Alcalay R, Caccappolo E, Mejia-Santana H, Tang M, Rosado L, Orbe Reilly M . Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol. 2013; 71(1):62-7. PMC: 3947132. DOI: 10.1001/jamaneurol.2013.4498. View

Hughes T, Ross H, Musa S, Bhattacherjee S, Nathan R, Mindham R . A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology. 2000; 54(8):1596-602. DOI: 10.1212/wnl.54.8.1596. View

Santangelo G, Vitale C, Picillo M, Moccia M, Cuoco S, Longo K . Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. Parkinsonism Relat Disord. 2015; 21(10):1219-26. DOI: 10.1016/j.parkreldis.2015.08.024. View

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

Garrido A, Fairfoul G, Tolosa E, Marti M, Green A . -synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson's disease. Ann Clin Transl Neurol. 2019; 6(6):1024-1032. PMC: 6562027. DOI: 10.1002/acn3.772. View

Breza M, Koutsis G, Karadima G, Potagas C, Kartanou C, Papageorgiou S . The different faces of the p. A53T alpha-synuclein mutation: A screening of Greek patients with parkinsonism and/or dementia. Neurosci Lett. 2017; 672:136-139. DOI: 10.1016/j.neulet.2017.12.015. View

Helmich R, Thaler A, van Nuenen B, Gurevich T, Mirelman A, Marder K . Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers. Neurology. 2014; 84(4):399-406. PMC: 4336002. DOI: 10.1212/WNL.0000000000001189. View

Trinh J, Zeldenrust F, Huang J, Kasten M, Schaake S, Petkovic S . Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord. 2018; 33(12):1857-1870. DOI: 10.1002/mds.27527. View

Lerche S, Schulte C, Srulijes K, Pilotto A, Rattay T, Hauser A . Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. Mov Disord. 2017; 32(12):1780-1783. DOI: 10.1002/mds.27199. View

10.

Avenali M, Toffoli M, Mullin S, McNeil A, Hughes D, Mehta A . Evolution of prodromal parkinsonian features in a cohort of mutation-positive individuals: a 6-year longitudinal study. J Neurol Neurosurg Psychiatry. 2019; 90(10):1091-1097. DOI: 10.1136/jnnp-2019-320394. View

11.

Bentivoglio A, Cortelli P, Valente E, Ialongo T, Ferraris A, Elia A . Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. Mov Disord. 2001; 16(6):999-1006. DOI: 10.1002/mds.10034. View

12.

Puschmann A, Ross O, Vilarino-Guell C, Lincoln S, Kachergus J, Cobb S . A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat Disord. 2009; 15(9):627-32. PMC: 2783246. DOI: 10.1016/j.parkreldis.2009.06.007. View

13.

Lesage S, Brice A . Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009; 18(R1):R48-59. DOI: 10.1093/hmg/ddp012. View

14.

Chahine L, Qiang J, Ashbridge E, Minger J, Yearout D, Horn S . Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol. 2013; 70(7):852-8. PMC: 3762458. DOI: 10.1001/jamaneurol.2013.1274. View

15.

Aarsland D, Andersen K, Larsen J, Perry R, Wentzel-Larsen T, Lolk A . The rate of cognitive decline in Parkinson disease. Arch Neurol. 2004; 61(12):1906-11. DOI: 10.1001/archneur.61.12.1906. View

16.

Tokutake T, Ishikawa A, Yoshimura N, Miyashita A, Kuwano R, Nishizawa M . Clinical and neuroimaging features of patient with early-onset Parkinson's disease with dementia carrying SNCA p.G51D mutation. Parkinsonism Relat Disord. 2013; 20(2):262-4. DOI: 10.1016/j.parkreldis.2013.11.008. View

17.

Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T . Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology. 2008; 70(24):2277-83. DOI: 10.1212/01.wnl.0000304039.11891.29. View

18.

Firbank M, Yarnall A, Lawson R, Duncan G, Khoo T, Petrides G . Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study. J Neurol Neurosurg Psychiatry. 2017; 88(4):310-316. DOI: 10.1136/jnnp-2016-313918. View

19.

Kehagia A, Barker R, Robbins T . Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010; 9(12):1200-1213. DOI: 10.1016/S1474-4422(10)70212-X. View

20.

Ibanez P, Lesage S, Lohmann E, Thobois S, De Michele G, Borg M . Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain. 2006; 129(Pt 3):686-94. DOI: 10.1093/brain/awl005. View